Study of ZIO-101 in Multiple Myeloma

Alaunos Therapeutics

Status and phase: Completed; Phase 2; Phase 1

Conditions: Multiple Myeloma

Treatments: Drug: ZIO-101 (Darinaparsin)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00303199

SGL2001

Details and patient eligibility

About

The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma

Enrollment: 35 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Subjects with multiple myeloma who have received at least two prior therapies and currently require therapy.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

35 participants in 1 patient group

Single Arm

Experimental group

Treatment:

Drug: ZIO-101 (Darinaparsin)